Aminoglycosides are polycationic, aminocyclitol-containing antibiotics that kill gram-negative bacteria by an irreversible mechanism involving ribosomal binding and disruption of the inner membrane. Their concentration-dependent bactericidal activity and prolonged post-antibiotic effect distinguish them mechanistically from beta-lactams and support once-daily dosing strategies that exploit peak concentration as the pharmacodynamic driver of efficacy.
Structure and Uptake. All clinically used aminoglycosides share a central aminocyclitol ring (streptamine or 2-deoxystreptamine) linked to amino sugar residues; the specific sugars and their substitution pattern determine spectrum, toxicity profile, and susceptibility to inactivating enzymes. Uptake into bacterial cells is a two-stage, energy-dependent process that explains several distinctive clinical features. The first stage, energy-dependent phase I (EDP-I), involves electrostatic binding of the polycationic drug to the negatively charged lipopolysaccharide (LPS) of the gram-negative outer membrane, displacing divalent cations (Mg2+, Ca2+) that normally stabilize LPS, and disrupting outer membrane integrity. This initial binding is responsible for the early membrane perturbation seen at sub-inhibitory concentrations. The second stage, energy-dependent phase II (EDP-II), requires the proton motive force (PMF) across the inner membrane to actively transport aminoglycosides into the cytoplasm; this explains why obligate anaerobes (which lack a PMF under anaerobic conditions) are intrinsically resistant to aminoglycosides.1
Mechanism of Bactericidal Action. Once inside the bacterial cytoplasm, aminoglycosides bind with high affinity to the 16S ribosomal RNA (rRNA) of the 30S ribosomal subunit at the decoding site (the A site, or aminoacyl-tRNA acceptor site). This binding causes misreading of messenger RNA (mRNA) codons, resulting in the incorporation of incorrect amino acids into nascent polypeptide chains and the production of aberrant, non-functional proteins. Some of these abnormal proteins become inserted into the inner membrane, creating membrane channels that allow further aminoglycoside entry — a self-amplifying process that produces the rapid, irreversible bactericidal activity characteristic of this class. This mechanism differs substantially from purely static ribosomal inhibitors (macrolides, tetracyclines) which compete for binding without causing membrane disruption or the self-amplifying uptake cycle.2
Spectrum of Activity. Aminoglycosides are primarily active against aerobic gram-negative bacilli including most Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Enterobacter species, Serratia marcescens, Proteus species, Providencia species), Pseudomonas aeruginosa, and Acinetobacter baumannii. Gentamicin and tobramycin have similar overall gram-negative activity, though tobramycin is approximately two- to four-fold more active than gentamicin against Pseudomonas aeruginosa in vitro, making it the preferred agent for Pseudomonas pulmonary infections (particularly in cystic fibrosis [CF] patients). Amikacin has the broadest spectrum because its 1-N-acyl substituent protects it from most aminoglycoside-modifying enzymes (AMEs), making it the agent of choice when gentamicin or tobramycin resistance is suspected. Aminoglycosides have no useful activity against obligate anaerobes, Streptococcus pneumoniae, or most streptococci when used as monotherapy, though low-level synergistic activity against streptococci and enterococci is exploited in combination regimens with cell wall-active agents.3
Pharmacodynamic Properties. The key pharmacodynamic (PD) driver of aminoglycoside efficacy is the Cmax/MIC ratio, where MIC (minimum inhibitory concentration) is the key denominator, classifying aminoglycosides as concentration-dependent killers. Maximum bactericidal activity is achieved when Cmax/MIC exceeds 8-10 for gram-negative organisms; this target underpins the rationale for extended-interval (once-daily or every 36-48 hour) dosing. The post-antibiotic effect (PAE) of aminoglycosides against gram-negative bacteria is substantial (2-8 hours depending on the organism and drug concentration), meaning significant bacterial growth suppression persists well after drug concentrations fall below the MIC. The adaptive resistance phenomenon — a transient, reversible reduction in aminoglycoside uptake that develops within hours of initial exposure — also supports extended dosing intervals, as a drug-free interval allows bacterial cells to lose adaptive resistance before the next dose.4
Aminoglycoside transport across the inner bacterial membrane (EDP-II) is driven by the electron transport chain and requires an intact proton motive force (PMF). Obligate anaerobes generate energy through substrate-level phosphorylation without an electron transport chain, and therefore lack the PMF necessary to drive active aminoglycoside uptake. Facultative anaerobes grown under strict anaerobic conditions also become resistant for the same reason. This explains why aminoglycosides have no role in anaerobic infections regardless of in vitro susceptibility testing results performed under aerobic conditions, and why intra-abdominal and pelvic infections require additional anaerobic coverage when aminoglycosides are used.
The pharmacokinetics of aminoglycosides are defined by their polycationic nature: poor oral bioavailability, limited volume of distribution reflecting hydrophilic distribution primarily in extracellular fluid, almost exclusive renal elimination, and a marked propensity for accumulation in renal cortical tissue and inner ear endolymph — the two compartments responsible for their principal toxicities. Understanding these properties is the foundation for rational dosing and toxicity prevention.
Absorption, Distribution, Metabolism, and Excretion (ADME). Aminoglycosides are not absorbed orally because their polycationic character prevents passive diffusion across gastrointestinal mucosa; oral administration is used only for bowel decontamination or treatment of hepatic encephalopathy (using neomycin, largely superseded). Intramuscular (IM) absorption is rapid and complete, but intravenous (IV) administration is standard in serious infections. The apparent volume of distribution (Vd) is approximately 0.25-0.3 L/kg in euvolemic adults, reflecting distribution predominantly into extracellular fluid. This Vd increases substantially in septic patients with third-space fluid accumulation (edema, ascites, effusions) and decreases in obese patients relative to total body weight; both scenarios require weight-based dosing adjustments — using ideal body weight (IBW) as the base and correcting for obesity using the adjusted body weight (AdjBW = IBW + 0.4 × [total body weight minus IBW]). Aminoglycosides are essentially eliminated unchanged by glomerular filtration, with a plasma half-life of approximately 2-3 hours in patients with normal renal function.5
Extended-Interval (Once-Daily) Dosing. Extended-interval aminoglycoside dosing (EID), also called once-daily dosing or high-dose extended-interval dosing, administers the entire daily aminoglycoside dose as a single infusion (typically every 24 hours in patients with normal renal function), generating a high Cmax that optimizes the Cmax/MIC (minimum inhibitory concentration) ratio while allowing a drug-free interval that limits tubular cell accumulation and adaptive resistance development. Gentamicin and tobramycin are typically dosed at 5-7 mg/kg/day as a single infusion; amikacin at 15-20 mg/kg/day. Efficacy of EID has been demonstrated to be equivalent or superior to multiple-daily dosing (MDD) in multiple randomized trials and meta-analyses across a range of gram-negative infections, with a consistent trend toward reduced nephrotoxicity. The Hartford nomogram is widely used to individualize EID intervals (q24h, q36h, or q48h) based on an 8-hour post-infusion level, guiding adjustment for varying degrees of renal function.5
Therapeutic Drug Monitoring. Therapeutic drug monitoring (TDM) is mandatory for aminoglycosides because of the narrow therapeutic index (TI) and the direct relationship between drug exposure and toxicity. For extended-interval dosing, a single level drawn 6-14 hours after the infusion is plotted on the Hartford nomogram to determine the appropriate dosing interval; levels falling in the acceptable zone of the nomogram predict acceptable efficacy and toxicity risk. For multiple-daily dosing (used in specific populations including endocarditis synergy regimens and neonates), peak levels (drawn 30-60 minutes after a 30-minute infusion) and trough levels (drawn immediately before the next dose) are both monitored. Target peaks for gentamicin/tobramycin MDD are typically 6-10 mcg/mL for gram-negative infections and 3-5 mcg/mL for synergy regimens; target troughs are below 2 mcg/mL (ideally below 1 mcg/mL) to minimize nephrotoxicity. Amikacin MDD target peaks are 20-30 mcg/mL; troughs below 8 mcg/mL.6
Special Populations and Dosing Challenges. Several patient populations require particular attention to aminoglycoside dosing. Patients with cystic fibrosis (CF) have markedly increased Vd and accelerated clearance due to altered body composition and enhanced renal tubular secretion; CF patients typically require higher doses (tobramycin 8-10 mg/kg/day or more) and more frequent monitoring.9 Neonates have a large Vd relative to body weight and immature renal function requiring individualized dosing; EID is used in full-term neonates but MDD may be preferred in premature infants. Patients with septic shock and augmented renal clearance (ARC): GFR (glomerular filtration rate) above 130 mL/min/1.73m2 may eliminate aminoglycosides faster than expected, resulting in subtherapeutic peaks; a first-dose pharmacokinetic level should be obtained in patients at risk for ARC. Patients receiving continuous renal replacement therapy (CRRT [continuous renal replacement therapy]) require individualized dosing based on effluent flow rates and frequent TDM.5
The Hartford nomogram plots a single serum aminoglycoside level drawn 6-14 hours after the start of a 7 mg/kg gentamicin or tobramycin infusion against the time of sampling. Patients whose level falls in the "OK" zone receive the next dose at 24 hours; levels in the "q36h" zone indicate reduced clearance requiring a 36-hour interval; levels in the "q48h" zone indicate further impaired clearance requiring a 48-hour interval. Levels above all zones suggest the dose is too high or clearance is severely impaired. The nomogram was derived from pharmacokinetic simulations targeting Cmax/MIC above 8-10 and troughs near zero, and has been validated in multiple clinical settings. It is not validated for neonates, pregnancy, significant burns, or ascites.
The two principal dose-limiting toxicities of aminoglycosides — nephrotoxicity and ototoxicity — are both caused by drug accumulation in specific cellular compartments with limited elimination capacity. Understanding the mechanisms of each and the clinical risk factors that amplify toxicity risk is essential for safe use, as both toxicities can be irreversible when recognized late and many risk factors are modifiable.
Nephrotoxicity: Mechanism and Incidence. Aminoglycoside nephrotoxicity results from preferential accumulation in the proximal tubular epithelial cells of the renal cortex. Aminoglycosides are freely filtered at the glomerulus and then taken up by active endocytosis into proximal tubular cells via the megalin-cubilin receptor complex (expressed on the luminal brush border), where they accumulate to concentrations many-fold higher than plasma. Intracellular accumulation impairs mitochondrial function, disrupts lysosomal membranes (phospholipidosis), generates reactive oxygen species (ROS [reactive oxygen species]), and ultimately causes proximal tubular cell death. The clinical manifestation is a non-oliguric acute kidney injury (AKI) that typically develops after 5-10 days of therapy, with rises in serum creatinine that may lag behind tubular injury by 24-48 hours. Incidence with conventional multiple-daily dosing ranges from 10-25%; extended-interval dosing reduces nephrotoxicity risk, as the drug-free trough period allows clearance of proximal tubular drug before the next accumulation cycle.8
Nephrotoxicity: Risk Factors and Prevention. Independent risk factors for aminoglycoside nephrotoxicity include pre-existing renal impairment, volume depletion, hypokalemia, hypomagnesemia, prolonged therapy duration (beyond 5-7 days), high trough concentrations, older age, liver disease (particularly cirrhosis with hepatorenal physiology), and concomitant nephrotoxin exposure. Nephrotoxic drug combinations requiring particular vigilance include concurrent vancomycin (vancomycin-aminoglycoside combination markedly increases nephrotoxicity risk beyond either agent alone), amphotericin B, cisplatin, cyclosporine, and radiographic contrast agents. Prevention strategies include maintaining adequate hydration and volume status, correcting electrolyte deficits before and during therapy, avoiding nephrotoxic co-medications when possible, using extended-interval dosing where appropriate, limiting course duration, and daily monitoring of serum creatinine with dose adjustment or agent substitution when AKI develops.8
Ototoxicity: Cochlear and Vestibular. Aminoglycoside ototoxicity results from irreversible destruction of sensory hair cells in the cochlea (causing sensorineural hearing loss [SNHL]) and vestibular apparatus (causing vestibular dysfunction with vertigo, oscillopsia, and gait ataxia). Aminoglycosides enter inner ear endolymph by an active uptake mechanism and accumulate in hair cells, where they generate ROS and activate apoptotic pathways, ultimately destroying the outer hair cells of the cochlear basal turn first (high-frequency hearing loss) and progressing to inner hair cells with more severe or prolonged exposure. Unlike nephrotoxicity, cochlear hair cell destruction is permanent because mammalian hair cells do not regenerate. Cochlear toxicity manifests initially as high-frequency hearing loss (4-8 kHz range, above the frequency range for speech) that may go undetected without audiometry; speech-frequency loss develops with more severe injury. Vestibular toxicity manifests as oscillopsia (inability to stabilize visual images during head movement), imbalance, and chronic disequilibrium that may persist for years after drug discontinuation.8
Ototoxicity: Agent Differences, Risk Factors, and Monitoring. The relative ototoxic potential differs among agents: streptomycin and gentamicin preferentially cause vestibulotoxicity; amikacin and tobramycin preferentially cause cochleotoxicity; neomycin (topical and oral only) is the most cochleotoxic aminoglycoside and must never be given systemically. Risk factors for ototoxicity include cumulative dose, prior aminoglycoside exposure (synergistic hair cell damage with re-exposure), concomitant ototoxic drugs (loop diuretics — particularly ethacrynic acid — and cisplatin), age extremes, pre-existing hearing loss, and genetic susceptibility variants. The mitochondrial 12S rRNA A1555G (adenine-to-guanine transition at position 1555) nucleotide substitution (mtDNA [mitochondrial DNA] variant) dramatically increases cochlear susceptibility to aminoglycoside ototoxicity and is identified through genetic testing in at-risk individuals or families; carriers may develop severe hearing loss after a single conventional aminoglycoside dose. Routine audiometric monitoring during prolonged aminoglycoside courses is recommended but rarely performed in acute inpatient settings; baseline audiometry before therapy initiation is recommended when feasible.10
The combination of vancomycin and an aminoglycoside carries a substantially higher nephrotoxicity risk than either agent alone. Multiple observational studies and meta-analyses have demonstrated that AKI rates of 20-35% or higher are associated with this combination, compared to approximately 5-15% for vancomycin monotherapy and 10-25% for aminoglycoside monotherapy. The combination is still used for specific indications (enterococcal endocarditis synergy, some gram-negative bacteremia regimens), but the nephrotoxicity risk mandates daily renal function monitoring, aggressive hydration, avoidance of additional nephrotoxins, and prompt dose adjustment or drug substitution when creatinine rises. The rationale for continuing the combination must be reassessed daily against the toxicity risk; vancomycin TDM guidelines recommend caution with nephrotoxic co-medications.7
The clinical role of aminoglycosides has narrowed since the 1980s as less toxic alternatives emerged for many gram-negative infections, but they retain important niches: serious Pseudomonas aeruginosa infections where combination therapy adds benefit, enterococcal endocarditis synergy regimens, multidrug-resistant gram-negative bacteremia, and inhaled tobramycin for cystic fibrosis lung disease. Resistance is mediated predominantly by aminoglycoside-modifying enzymes (AME [aminoglycoside-modifying enzyme], plural AMEs) encoded on transferable plasmids — a resistance mechanism with significant epidemiological implications.
Gram-Negative Bacteremia and Sepsis. Aminoglycosides were historically first-line agents for gram-negative bacteremia and sepsis, but their use has shifted substantially toward adjunctive or combination roles as carbapenems, extended-spectrum cephalosporins, and novel beta-lactam-inhibitor combinations became available. Current evidence from randomized trials and systematic reviews does not support the routine addition of an aminoglycoside to a beta-lactam for gram-negative bacteremia caused by susceptible organisms in non-immunocompromised patients, as combination therapy does not improve mortality compared to beta-lactam monotherapy while substantially increasing nephrotoxicity. However, aminoglycosides retain a role in initial empiric coverage of septic shock when multidrug-resistant gram-negative organisms are suspected, as broad empiric coverage is more critical than toxicity avoidance in the first 24-48 hours of severe sepsis; the aminoglycoside is typically discontinued once susceptibility data are available and clinical stability is established.3
Pseudomonas aeruginosa Infections. Tobramycin is preferred over gentamicin for Pseudomonas aeruginosa infections because of its superior intrinsic potency (approximately two- to four-fold lower MIC). In severe Pseudomonas infections including pneumonia, bacteremia, and endocarditis, combination therapy with an antipseudomonal beta-lactam is standard practice at most institutions, though the benefit of the aminoglycoside component beyond the beta-lactam remains debated for susceptible organisms in non-neutropenic patients. In neutropenic patients and those with severe immunosuppression, combination therapy is more strongly supported. Inhaled tobramycin (tobramycin inhalation solution [TIS] or tobramycin inhalation powder [TIP]) achieves very high airway concentrations with minimal systemic exposure and is approved for chronic suppression of Pseudomonas in CF (cystic fibrosis) patients, where it reduces exacerbation frequency and slows pulmonary decline without the systemic toxicity burden of parenteral dosing.11
Endocarditis Synergy Regimens. Aminoglycosides at low doses exploit synergy with cell wall-active agents to enhance bactericidal killing against gram-positive organisms including enterococci and streptococci. For enterococcal endocarditis caused by gentamicin-susceptible Enterococcus faecalis (defined as gentamicin MIC below 500 mcg/mL, i.e., absence of high-level aminoglycoside resistance [HLAR]), gentamicin 3 mg/kg/day in divided doses (1 mg/kg every 8 hours) combined with ampicillin or vancomycin for 4-6 weeks was historically the standard of care. However, the combination ampicillin plus ceftriaxone has demonstrated equivalent efficacy to ampicillin plus gentamicin for E. faecalis endocarditis with substantially less nephrotoxicity in the PENTA (Partial Endocarditis Treatment Alternative) trial and subsequent data, and is now preferred at many centers, limiting gentamicin synergy use to specific situations including streptococcal endocarditis where short-course gentamicin (2-week synergy) remains guideline-supported.12
Resistance Mechanisms. The dominant mechanism of aminoglycoside resistance in clinical practice is enzymatic inactivation by aminoglycoside-modifying enzymes (AMEs), which include three classes: acetyltransferases (AACs [aminoglycoside acetyltransferases]), nucleotidyltransferases (ANTs [aminoglycoside nucleotidyltransferases]), and phosphotransferases (APHs [aminoglycoside phosphotransferases]). Each enzyme class modifies specific hydroxyl or amino groups on the aminoglycoside ring structure, abolishing ribosomal binding. AMEs are encoded on mobile genetic elements (plasmids, transposons, integrons), enabling horizontal transfer among Enterobacteriaceae, Pseudomonas, and Acinetobacter. Amikacin resistance to most AMEs is blocked by its 1-N-acyl substituent (the amikacin-specific side chain), which sterically prevents modification, explaining amikacin's broader activity in the face of AME-mediated resistance. Additional resistance mechanisms include 16S rRNA methyltransferases (RMTases [ribosomal RNA methyltransferases]) encoded by genes such as armA and rmtB, which methylate the 30S ribosomal binding site and confer high-level pan-aminoglycoside resistance including amikacin; RMTases are increasingly found co-expressed with NDM (New Delhi metallo-beta-lactamase) and other carbapenemases, creating pan-resistant isolates.1
| Agent | Spectrum Highlight | Standard Dose (EID) | Target Cmax/MIC | Principal Toxicity Risk | Key Clinical Use |
|---|---|---|---|---|---|
| Gentamicin | Broad gram-neg; enterococcal synergy | 5-7 mg/kg q24h | ≥8-10 | Vestibulotoxicity > cochleotoxicity; nephrotoxicity | Gram-neg bacteremia; enterococcal endocarditis synergy |
| Tobramycin | Pseudomonas (2-4× more potent than gentamicin) | 5-7 mg/kg q24h IV; inhaled for CF | ≥8-10 | Cochleotoxicity > vestibulotoxicity; nephrotoxicity | Pseudomonas bacteremia/pneumonia; CF inhaled suppression |
| Amikacin | Broadest (1-N-acyl group resists most AMEs) | 15-20 mg/kg q24h | ≥8-10 | Cochleotoxicity; nephrotoxicity | Gentamicin/tobramycin-resistant gram-neg; MDR organisms |
| Streptomycin | Mycobacterium tuberculosis; Yersinia; Brucella; enterococcal synergy | 15 mg/kg IM q24h (TB) | N/A (TB dosing) | Vestibulotoxicity (severe); cochleotoxicity | TB (drug-resistant); plague; tularemia; brucellosis |
| Neomycin | Gram-neg decontamination; Staphylococci (topical) | Oral/topical ONLY | N/A | Most cochleotoxic — systemic use absolutely contraindicated | Bowel prep; hepatic encephalopathy; topical wound care |
16S rRNA methyltransferases (RMTases) encoded by armA, rmtA through rmtH, and npmA genes methylate the aminoglycoside binding site on the 16S rRNA, conferring high-level resistance (MIC above 256 mcg/mL) to all clinically used aminoglycosides including amikacin. RMTase genes are frequently co-located with genes encoding NDM and other carbapenemases on the same mobile plasmids, creating organisms resistant to essentially all conventional antibiotics. Detection requires genotypic testing (PCR or whole-genome sequencing [WGS]), as phenotypic aminoglycoside susceptibility testing may not reliably identify the resistance mechanism. When RMTase-positive, pan-resistant organisms are identified, therapy options are severely limited and require specialist infectious disease and microbiology input; plazomicin (a next-generation aminoglycoside with RMTase stability) and novel combinations including cefiderocol may be considered.
Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43(4):727-737.
doi:10.1128/AAC.43.4.727Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature. 1987;327(6121):389-394.
doi:10.1038/327389a0Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;1:CD003344.
doi:10.1002/14651858.CD003344.pub3Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-12.
doi:10.1086/516284Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655.
doi:10.1128/AAC.39.3.650Streetman DS, Nafziger AN, Destache CJ, Bertino JS Jr. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21(4):443-451.
doi:10.1592/phco.21.5.443.34490Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82-98.
doi:10.2146/ajhp080434Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003-1012.
doi:10.1128/AAC.43.5.1003Corcoran TE, Smaldone GC, Bahrani-Mougeot FK, et al. Pharmacokinetics and safety of inhaled tobramycin in critically ill patients. J Aerosol Med. 2006;19(1):68-78.
doi:10.1089/jam.2006.19.68Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics. 2005;6(1):27-36.
doi:10.1517/14622416.6.1.27Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340(1):23-30.
doi:10.1056/NEJM199901073400104Fernandez-Hidalgo N, Almirante B, Gavalda J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013;56(9):1261-1268.
doi:10.1093/cid/cit052